Results for: Boston Scientific

Boston Scientific Corporation (BSX) reported impressive first-quarter earnings, exceeding analyst expectations. The company’s revenue reached $3.86 billion, surpassing the estimated $3.69 billion. Sales experienced significant growth across all segments, with the cardiovascular segment leading the way with a rise of over $2.4 billion. Boston Scientific also raised its 2024 guidance, forecasting net sales growth of 11%-13% and adjusted EPS of $2.29-$2.34, both higher than previous estimates. The company’s strong performance and positive outlook contributed to a 6.02% surge in BSX shares, reaching $73.15 during Wednesday’s trading session.

Boston Scientific Corporation (NYSE: BSX) reported strong financial results for the first quarter of 2024, driven by growth in its diversified businesses. Net sales increased by 13.8% on a reported basis, 15.0% on an operational basis, and 13.1% on an organic basis compared to the prior year. The company also raised its full-year guidance, reflecting continued momentum.